Literature DB >> 16100140

Acute respiratory failure due to pneumocystis pneumonia in patients without human immunodeficiency virus infection: outcome and associated features.

Emir Festic1, Ognjen Gajic, Andrew H Limper, Timothy R Aksamit.   

Abstract

OBJECTIVE: To examine outcome and associated factors of acute respiratory failure (ARF) in non-HIV-related Pneumocystis pneumonia (PCP) in patients admitted to a medical ICU between 1995 and 2002.
DESIGN: A retrospective review of medical records and an APACHE (acute physiology and chronic health evaluation) III database.
SETTING: Academic tertiary medical center.
RESULTS: We identified 30 patients with non-HIV-related PCP and ARF. In-hospital, 6-month, and 1-year mortality rates were 67%, 77%, and 80%, respectively. Median age was 63.5 years. Median APACHE III score on day 1 was 65.5. Median ICU and hospital lengths of stay were 13 days and 21 days, respectively. All seven patients having a pneumothorax died. All but one patient had an elevated lactate dehydrogenase level (median, 563 U/L). The diagnosis was made using BAL in 28 patients and by transbronchial biopsy in the remaining 2 patients. All patients were immunosuppressed (eight were receiving corticosteroids, seven were receiving chemotherapy, and the remainder received both). Median immunosuppressive prednisone-equivalent dose was 40 mg (median length of treatment, 4.5 months). Not a single patient received PCP prophylaxis. All but one patient required intubation and invasive positive pressure ventilation (PPV). Hospital mortality was associated with high APACHE III scores on day 1 (p = 0.05), intubation delay (p = 0.03), length of PPV (p = 0.003), and development of pneumothorax (p = 0.033). Logistic regression analysis demonstrated that association of intubation delay with hospital mortality persisted after adjusting for severity of illness (p = 0.03).
CONCLUSIONS: Among patients with ARF secondary to non-HIV-related PCP, poor prognostic factors include high APACHE III scores, intubation delay, longer duration of PPV, and development of pneumothorax. None of the patients in this series received PCP prophylaxis prior to the development of pneumonia.

Entities:  

Mesh:

Year:  2005        PMID: 16100140     DOI: 10.1378/chest.128.2.573

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  52 in total

Review 1.  Update on the diagnosis and treatment of Pneumocystis pneumonia.

Authors:  Eva M Carmona; Andrew H Limper
Journal:  Ther Adv Respir Dis       Date:  2010-08-24       Impact factor: 4.031

2.  Underlying renal insufficiency: the pivotal risk factor for Pneumocystis jirovecii pneumonia in immunosuppressed patients with non-transplant glomerular disease.

Authors:  Wen-Ling Ye; Nan Tang; Yu-Bing Wen; Hang Li; Min-Xi Li; Bin Du; Xue-Mei Li
Journal:  Int Urol Nephrol       Date:  2016-06-28       Impact factor: 2.370

3.  Cost-effectiveness of Prophylaxis Against Pneumocystis jiroveci Pneumonia in Patients with Crohn's Disease.

Authors:  Philip N Okafor; Francis A Farraye; Adetoro T Okafor; Daniel O Erim
Journal:  Dig Dis Sci       Date:  2015-07-16       Impact factor: 3.199

Review 4.  Noninvasive ventilation for acute respiratory failure: a review of the literature and current guidelines.

Authors:  Katherine Margaret Berg; Peter Clardy; Michael William Donnino
Journal:  Intern Emerg Med       Date:  2012-09-28       Impact factor: 3.397

Review 5.  Noninvasive ventilation in trauma.

Authors:  Marcin K Karcz; Peter J Papadakos
Journal:  World J Crit Care Med       Date:  2015-02-04

6.  Pneumocystis jiroveci Pneumonia in an Atypical Host.

Authors:  Raquel E Reinbolt; Shadia Alam; Rachel Layman; Charles Shapiro; Maryam Lustberg
Journal:  Clin Breast Cancer       Date:  2011-12-01       Impact factor: 3.225

7.  Multicenter, prospective clinical evaluation of respiratory samples from subjects at risk for Pneumocystis jirovecii infection by use of a commercial real-time PCR assay.

Authors:  Philippe M Hauser; Jacques Bille; Cornelia Lass-Flörl; Christian Geltner; Marta Feldmesser; Michael Levi; Hitesh Patel; Victoria Muggia; Barbara Alexander; Martin Hughes; Sarah A Follett; Xiaohui Cui; Flora Leung; Gillian Morgan; Adrian Moody; David S Perlin; David W Denning
Journal:  J Clin Microbiol       Date:  2011-03-02       Impact factor: 5.948

8.  Efficacy of caspofungin combined with trimethoprim/sulfamethoxazole as first-line therapy to treat non-HIV patients with severe pneumocystis pneumonia.

Authors:  Gensheng Zhang; Miaomiao Chen; Shufang Zhang; Hongwei Zhou; Xiaozhen Ji; Jiachang Cai; Tianzheng Lou; Wei Cui; Ning Zhang
Journal:  Exp Ther Med       Date:  2017-11-16       Impact factor: 2.447

9.  Pneumocystis pneumonia in a non-HIV patient on chronic corticosteroid therapy: a question of prophylaxis.

Authors:  Michael J Plakke; Leena Jalota; Benjamin J Lloyd
Journal:  BMJ Case Rep       Date:  2013-03-01

10.  Virtual Screening of Phytochemicals to Novel Target (HAT) Rtt109 in Pneumocystis Jirovecii using Bioinformatics Tools.

Authors:  Ramya Sugumar; Abhinand Ponneri Adithavarman; Anusha Dakshinamoorthi; Darling Chellathai David; Padmavathi Kannan Ragunath
Journal:  J Clin Diagn Res       Date:  2016-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.